ResearcherGuangzhou Medical UniversityActive in the last 2 years

Jie Yang

Verified by OpenAlex author ID (good confidence)As of 11 November 2026

Matched on OpenAlex author ID A5101647977.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Collaborators: 4

Papers, trials and grants by year

2024: 2 papers

Papers 2

Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. Co-author DOI 10.1016/j.isci.2024.110496 ↗
Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study. First author DOI 10.3389/fonc.2024.1370009 ↗

Closest collaborators

The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Peng Ning · 1 shared paper, 2024
- Paper Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a populatio… DOI 10.3389/fonc.2024.1370009 ↗
Qingtian Huang · 1 shared paper, 2024
- Paper Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. DOI 10.1016/j.isci.2024.110496 ↗
Ling Qi · 1 shared paper, 2024
- Paper Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. DOI 10.1016/j.isci.2024.110496 ↗
Fengjin Li · 1 shared paper, 2024
- Paper Eupalinolide B suppresses pancreatic cancer by ROS generation and potential cuproptosis. DOI 10.1016/j.isci.2024.110496 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.